Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
VistaGen Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.51 | -$0.46 | -$0.50 |
| Q2 2025 | 1 | -$0.45 | -$0.45 | -$0.45 |
| Q3 2025 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q4 2025 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q1 2026 | 1 | -$0.45 | -$0.45 | -$0.45 |
VistaGen Therapeutics, Inc. Earnings Date And Information
VistaGen Therapeutics, Inc. last posted its earnings results on Thursday, February 13th, 2025. The company reported $-0.46 earnings per share for the quarter, topping analysts' consensus estimates of $-0.48 by $0.02. The company had revenue of 234,000 for the quarter and had revenue of 1.06 M for the year. VistaGen Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.52 diluted earnings per share) and currently has a price-to-earnings ratio of -1.7. VistaGen Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, June 9th, 2025 based on prior year's report dates.
VistaGen Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/13/2025 | Q3 2025 | -$0.48 | -$0.46 | 0.02 | $308,500 | $234,000 |
| 11/07/2024 | Q2 2025 | -$0.40 | -$0.42 | -0.02 | $224,667 | $183,000 |
| 08/13/2024 | Q1 2025 | -$0.41 | -$0.35 | 0.06 | $298,650 | $84,000 |
| 06/11/2024 | Q4 2024 | -$0.34 | -$0.35 | -0.01 | N/A | $197,300 |
| 02/13/2024 | Q3 2024 | -$0.31 | -$0.43 | -0.12 | $726,000 | $411,400 |
| 11/09/2023 | Q2 2024 | -$0.68 | -$0.66 | 0.02 | $184,600 | $278,000 |
| 08/10/2023 | Q1 2024 | -$0.86 | -$0.94 | -0.08 | $184,600 | $177,000 |
| 06/28/2023 | Q4 2023 | N/A | -$1.71 | N/A | N/A | $175,600 |
| 02/07/2023 | Q3 2023 | -$1.80 | -$1.42 | 0.38 | N/A | $179,600 |
| 11/10/2022 | Q2 2023 | -$2.40 | -$2.54 | -0.14 | $310,050 | $-892,500 |
| 08/11/2022 | Q1 2023 | -$2.70 | -$2.87 | -0.17 | $238,633 | $310,100 |
| 06/23/2022 | Q4 2022 | -$1.80 | -$2.43 | -0.63 | N/A | $38,900 |
| 02/10/2022 | Q3 2022 | -$2.40 | -$1.56 | 0.84 | N/A | $357,900 |
| 11/10/2021 | Q2 2022 | -$1.50 | -$1.99 | -0.49 | $351,367 | $358,000 |
| 08/12/2021 | Q1 2022 | -$1.50 | -$1.22 | 0.28 | $394,633 | $354,100 |
| 06/29/2021 | Q4 2021 | -$1.50 | -$1.29 | 0.21 | N/A | $441,900 |
| 02/11/2021 | Q3 2021 | -$1.50 | -$1.96 | -0.46 | N/A | $313,600 |
| 11/12/2020 | Q2 2021 | $0.60 | -$1.47 | -2.07 | $2.50 M | $334,000 |
| 08/13/2020 | Q1 2021 | -$3.00 | -$1.83 | 1.17 | N/A | $0 |
| 06/29/2020 | Q4 2020 | -$3.00 | -$2.08 | 0.92 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
VistaGen Therapeutics, Inc. Earnings: FAQ's
VistaGen Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, June 9th, 2025 based offlast year's report dates.
In the previous quarter, VistaGen Therapeutics, Inc. (:VTGN) reported $-0.46 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.48 by $0.02.
The conference call for VistaGen Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for VistaGen Therapeutics, Inc.'s latest earnings report can be read online.
VistaGen Therapeutics, Inc. (:VTGN) has a recorded annual revenue of $1.06 M.
VistaGen Therapeutics, Inc. (:VTGN) has a recorded net income of $-29,362,000.VistaGen Therapeutics, Inc. has generated $-1.52 earnings per share over the last four quarters.
VistaGen Therapeutics, Inc. (:VTGN) has a price-to-earnings ratio of -1.7 and price/earnings-to-growth ratio is 0.88.